OTCMKTS:VYNT Vyant Bio (VYNT) Stock Price, News & Analysis $0.19 +0.01 (+7.78%) As of 12/29/2023 Add Compare Share Share Stock Analysis Stock Analysis About Vyant Bio Stock (OTCMKTS:VYNT) Get Vyant Bio alerts:Sign Up Key Stats Today's Range$0.18▼$0.2050-Day Range$0.19▼$0.1952-Week Range$0.14▼$1.58Volume19,100 shsAverage Volume161,822 shsMarket Capitalization$1.23 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Vyant Bio, Inc. is a biotechnology company focused on improving drug discovery and development through human-relevant biological models and data-driven research. The company developed platforms designed to help pharmaceutical and biotechnology organizations evaluate potential therapies and better understand disease biology before clinical testing. Its activities have included the development and use of patient-derived cells, organoids, stem-cell-based models and other advanced preclinical systems. These technologies were intended to support research in areas such as oncology, neurological disorders and other complex diseases, with services spanning assay development, drug screening, toxicology and preclinical testing. Vyant Bio was formerly known as Cancer Genetics, Inc. and adopted its current name as it expanded beyond cancer-focused genomic testing and research services. The company operated through a combination of internal platforms and acquired businesses serving pharmaceutical and biotechnology customers. Publicly available information about its current operations, leadership and geographic reach is limited.AI Generated. May Contain Errors. Read More Receive VYNT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vyant Bio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VYNT Stock News HeadlinesVyant Bio files Certificate of Dissolution with State of DelawareDecember 26, 2023 | msn.comVyant Bio Inc VYNTDecember 19, 2023 | morningstar.comMYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.October 6 at 1:00 AM | Profits Run (Ad)Vyant Bio, Inc.: Vyant Bio Provides Update on Winddown ActivitiesNovember 11, 2023 | finanznachrichten.deVyant Bio expects to start liquidation payments in Q4 2024November 10, 2023 | msn.comVyant Bio Provides Update on Winddown ActivitiesNovember 10, 2023 | finance.yahoo.comVyant Bio, Inc.: Vyant Bio Announces Stockholder Approval of Plan of DissolutionNovember 1, 2023 | finanznachrichten.deVyant Bio shareholders approve plan to dissolve companyNovember 1, 2023 | msn.comSee More Headlines VYNT Stock Analysis - Frequently Asked Questions How have VYNT shares performed this year? Vyant Bio's stock was trading at $0.1940 at the beginning of 2026. Since then, VYNT shares have increased by 0.0% and is now trading at $0.1940. How were Vyant Bio's earnings last quarter? Vyant Bio, Inc. (OTCMKTS:VYNT) posted its earnings results on Thursday, November, 11th. The company reported ($0.75) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.75). The firm had revenue of $1.51 million for the quarter, compared to analyst estimates of $2.19 million. Vyant Bio had a negative net margin of 3,474.81% and a negative trailing twelve-month return on equity of 151.82%. Read the conference call transcript. When did Vyant Bio's stock split? Vyant Bio's stock reverse split on Wednesday, November 2nd 2022.The 1-5 reverse split was announced on Wednesday, November 2nd 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 2nd 2022. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. How do I buy shares of Vyant Bio? Shares of VYNT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Vyant Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vyant Bio investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), Alphabet (GOOG) and JPMorgan Chase & Co. (JPM). Company Calendar Last Earnings11/11/2021Today10/06/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Medical laboratories Sub-IndustryHealthcare Current SymbolOTCMKTS:VYNT CIK1349929 Webvyantbio.com Phone(201) 479-1357Fax201-528-9201Employees30Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$22.69 million Net Margins-3,474.81% Pretax Margin-3,281.86% Return on Equity-151.82% Return on Assets-97.14% Debt Debt-to-Equity Ratio0.04 Current Ratio2.86 Quick Ratio2.86 Sales & Book Value Annual Sales$670 thousand Price / Sales1.83 Cash FlowN/A Price / Cash FlowN/A Book Value$1.69 per share Price / Book0.11Miscellaneous Outstanding Shares6,330,000Free Float5,724,000Market Cap$1.23 million OptionableNot Optionable Beta1.73 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (OTCMKTS:VYNT) was last updated on 10/6/2026 by MarketBeat.com Staff. From Our PartnersNvidia’s record quarter could send this new type of AI soaringNvidia just posted 96.2 billion in revenue for a single quarter, more than Coca-Cola generates in an entire ye...Brownstone Research | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredA weekly dividend fund holding Nvidia and PalantirCrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...Investors Alley | SponsoredDo this before December or regret itPorter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monet...Porter & Company | SponsoredThis list won't be up much longerBill Poulos and his team rebuild their Top 10 Stocks to Buy This Quarter report from scratch every quarter, pu...Profits Run | SponsoredFirst Look: Elon’s “Starphone”Rumors are swirling that Elon Musk is developing a new mobile device that could rival the iPhone. It's said to...Stansberry Research | SponsoredI've seen this movie before (last time: 17,556%)My track record speaks for itself... KDA: 17,556%. PRE: 3,900%. OCEAN: 2,650%. Every single one was called ...Crypto 101 Media | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vyant Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vyant Bio With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
